Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test
Dow Jones2026/09/24 16:22By Elias Schisgall
Shares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.
The stock was up 5.6% at $114.59 as of midday Thursday. Shares have risen 34% this year.
The company on Wednesday said a panel on the Food and Drug Administration's Medical Devices Advisory Committee voted to approve its premarket approval application for Galleri.
The panel voted seven to two with one abstention that the test's benefits outweigh its risks, six to four that the test was effective, and unanimously in support of its safety.
"Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test," Grail Chief Executive Josh Ofman said. "GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test."
Galleri received a breakthrough devices designation from the FDA in 2018. The company submitted its PMA application to the FDA early this year, and the agency is expected to make a final decision in the coming months.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
September 24, 2026 12:22 ET (16:22 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns
Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.
Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600
Morgan Stanley stated that Microsoft's stock price has recently rebounded, so the tech giant will face a "higher hurdle" if it wants to maintain its upward momentum.
Report: OpenAI plans to accelerate fundraising before Anthropic goes public
OpenAI is racing against time—in order to secure funding ahead of rival Anthropic’s IPO, the company has significantly compressed its fundraising timeline, aiming to complete approximately $30 billion in private financing, which could push its valuation past $1.4 trillion upon completion. Major investors such as SoftBank and MGX are already engaged in discussions. Both AI giants are targeting trillion-dollar valuations, and their largely overlapping investor bases are being forced to make simultaneous bets on both ventures within just a few days.
Crypto prices
More
